Visual storytelling for medical publications
2022-10-04 10:30
Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study
Results from
#NICHE
-2 study demonstrate impressive 95% major pathologic response rate in MMR-deficient
#coloncancer
with neoadjuvant
#ipilimumab
and
#nivolumab
https://bit.ly/3S6GksV
#VisualAbstract
@mdwrtcom